[1] Okamoto H, Tsuda F, Sakugawa H, et al. Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes. J Gen Virol, 1988,69 ( Pt 10):2575-2583.
[2] Lin CL, Kao JH. Natural history of acute and chronic hepatitis B: the role of HBV genotypes and mutants. Best Pract Res Clin Gastroenterol, 2017,31:249-255.
[3] Araujo NM. Hepatitis B virus intergenotypic recombinants worldwide: an overview. Infect Genet Evol, 2015,36:500-510.
[4] Yang J, Xing K, Deng R, et al. Identification of hepatitis B virus putative intergenotype recombinants by using fragment typing. J Gen Virol, 2006,87:2203-2215.
[5] Cui C, Shi J, Hui L, et al. The dominant hepatitis B virus genotype identified in Tibet is a C/D hybrid. J Gen Virol, 2002,83:2773-2777.
[6] Santana LC, Mantovani NP, Ferreira MC, et al. Identification of a new hepatitis B virus recombinant D2/D3 in the city of S?o Paulo, Brazil. Arch Virol, 2017,162:457-467.
[7] Lee SY, Lee SH, Kim JE, et al. Identification of Novel A2/C2 Inter-Genotype Recombinants of Hepatitis B Virus from a Korean Chronic Patient Co-Infected with Both Genotype A2 and C2. Int J Mol Sci, 2017,18:737.
[8] Zhang ZH, Wu CC, Chen XW, et al. Genetic variation of hepatitis B virus and its significance for pathogenesis. World J Gastroenterol, 2016,22:126-144.
[9] Liu CJ, Kao JH. Global perspective on the natural history of chronic hepatitis B: role of hepatitis B virus genotypes A to J. Semin Liver Dis, 2013,33:97-102.
[10] Zeng G, Wang Z, Wen S, et al. Geographic distribution, virologic and clinical characteristics of hepatitis B virus genotypes in China. J Viral Hepat, 2005,12:609-617.
[11] Al-Qahtani AA, Pourkarim MR, Trov?o NS, et al. Molecular epidemiology, phylogenetic analysis and genotype distribution of hepatitis B virus in Saudi Arabia: Predominance of genotype D1. Infect Genet Evol, 2020,77:104051.
[12] Saikia A, Bose M, Barman NN, et al. Molecular epidemiology of HBV infection in chronic hepatitis B virus infected patients in northeast India. J Med Virol, 2015,87:1539-1548.
[13] Sagnelli C, Ciccozzi M, Alessio L, et al. HBV molecular epidemiology and clinical condition of immigrants living in Italy. Infection, 2018,46:523-531.
[14] Pettersson JH, Myking S, Elshaug H, et al. Molecular epidemiology of hepatitis B virus infection in Norway. BMC Infect Dis, 2019,19:236.
[15] Mayerat C, Mantegani A, Frei PC. Does hepatitis B virus (HBV) genotype influence the clinical outcome of HBV infection? J Viral Hepat, 1999,6:299-304.
[16] Marciano S, Galdame OA, Gadano AC. HBV genotype F: natural history and treatment. Antivir Ther, 2013,18:485-488.
[17] Wolf JM, Pereira VRZB, Simon D, et al. Evolutionary history of hepatitis B virus genotype H. J Med Virol, 2021,93:4004-4009.
[18] Thakur V, Guptan RC, Kazim SN, et al. Profile, spectrum and significance of HBV genotypes in chronic liver disease patients in the Indian subcontinent. J Gastroenterol Hepatol, 2002,17:165-170.
[19] Orito E, Mizokami M. Hepatitis B virus genotypes and hepatocellular carcinoma in Japan. Intervirology, 2003,46:408-412.
[20] Yu MW, Yeh SH, Chen PJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst, 2005,97:265-272.
[21] Chan HL, Hui AY, Wong ML, et al. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut, 2004,53:1494-1498.
[22] Zhong YW, Di FL, Liu C, et al. Hepatitis B virus basal core promoter/precore mutants and association with liver cirrhosis in children with chronic hepatitis B virus infection. Clin Microbiol Infect, 2016,22:379.e1-379.e8.
[23] Yuen MF, Tanaka Y, Mizokami M, et al. Role of hepatitis B virus genotypes Ba and C, core promoter and precore mutations on hepatocellular carcinoma: a case control study. Carcinogenesis, 2004,25:1593-1598.
[24] Buti M, Cotrina M, Valdes A, et al. Is hepatitis B virus subtype testing useful in predicting virological response and resistance to lamivudine? J Hepatol, 2002,36:445-446.
[25] 蒋孝华, 李小芬, 蔡亚平, 等. HBV基因型与耐药变异的关系. 中国感染控制杂志, 2009,8:160-163.
[26] Akuta N, Suzuki F, Kobayashi M, et al. The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment. J Hepatol, 2003,38:315-321.
[27] Orito E, Fujiwara K, Tanaka Y, et al. A case-control study of response to lamivudine therapy for 2 years in Japanese and Chinese patients chronically infected with hepatitis B virus of genotypes Bj, Ba and C. Hepatol Res, 2006,35:127-134.
[28] 张莉, 孟现民, 董平. 上海市公共卫生临床中心2015—2019年乙型肝炎病毒基因突变分析. 肝脏, 2020,25:1043-1047.
[29] Kao JH, Wu NH, Chen PJ, et al. Hepatitis B genotypes and the response to interferon therapy. J Hepatol, 2000,33:998-1002.
[30] Erhardt A, Blondin D, Hauck K, et al. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut, 2005,54:1009-1013.
[31] Boglione L, D'Avolio A, Cariti G, et al. Sequential therapy with entecavir and PEG-INF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes. J Viral Hepat, 2013,20:e11-19.
[32] Tian Q, Jia J. Hepatitis B virus genotypes: epidemiological and clinical relevance in Asia. Hepatol Int, 2016,10:854-860.
[33] Kato M, Hamada-Tsutsumi S, Okuse C, et al. Effects of vaccine-acquired polyclonal anti-HBs antibodies on the prevention of HBV infection of non-vaccine genotypes. J Gastroenterol, 2017,52:1051-1063.
[34] Sugiyama M, Tanaka Y, Sakamoto T, et al. Early dynamics of hepatitis B virus in chimeric mice carrying human hepatocytes monoinfected or coinfected with genotype G. Hepatology, 2007,45:929-937.
[35] 胡晓勤, 叶慧. 不同HBV基因型患者血清miR-122、miR-155与HBV病毒载量之间的关系. 河北医药, 2019,41:485-488,493. |
